News
11-21-2011, 06:31 AM
Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.
More... (http://www.news-medical.net/news/20111121/Multi-center-cabozantinib-IST-for-hormone-receptor-positive-breast-cancer-with-bone-metastases-initiated.aspx)
More... (http://www.news-medical.net/news/20111121/Multi-center-cabozantinib-IST-for-hormone-receptor-positive-breast-cancer-with-bone-metastases-initiated.aspx)